Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from TYK Medicines, Inc. Class H ( (HK:2410) ).
TYK Medicines, Inc. has completed the conversion of 4,608,000 unlisted shares into H shares, with trading of these converted H shares on the Hong Kong Stock Exchange set to begin on March 5, 2026. Following the conversion, all 380,065,818 issued shares of the company are now H shares, simplifying the capital structure and potentially improving liquidity for existing and prospective investors.
The company’s H shares now represent 100% of its share capital, compared with 98.79% before the transaction, eliminating the previous portion of unlisted shares. The board has cautioned shareholders and potential investors to exercise care when dealing in the company’s H shares, underscoring that the change may influence trading dynamics and market perceptions of the stock.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc. is a joint stock company incorporated in the People’s Republic of China and listed on the Hong Kong Stock Exchange. The company is part of the pharmaceutical and biotechnology sector, focusing on drug development and healthcare-related products for domestic and international capital markets through its H share listing in Hong Kong.
Average Trading Volume: 2,782,291
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.62B
For a thorough assessment of 2410 stock, go to TipRanks’ Stock Analysis page.